Table III.
Correlation between clinicopathological parameters and immunoreactivity for HSP90, p53, E-cadherin and HPV in oral squamous cell carcinoma.
| Parameter | HSP90, n (%) | p53, n (%) | E-cadherin, n (%) | HPV16/18, n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Positive | p-value | Negative | Positive | p-value | Negative | Positive | p-value | Negative | Positive | p-value | |
| Age | ||||||||||||
| < 60 years | 6 (25.0) |
18 (75.0) |
0.915a | 15 (62.5) |
9 (37.5) |
0.327a | 8 (33.3) |
16 (66.7) |
0.699a | 19 (79.2) |
5 (20.8) |
0.492a |
| ≥ 60 years | 11 (26.2) |
31 (73.8) |
21 (50.0) |
21 (50.0) |
16 (38.1) |
26 (61.9) |
36 (85.7) |
6 (14.3) |
||||
| Gender | ||||||||||||
| Female | 7 (31.8) |
15 (68.2) |
0.426a | 14 (63.6) |
8 (36.4) |
0.294a | 8 (36.4) |
14 (63.6) |
1.000a | 19 (86.4) |
3 (13.6) |
0.640a |
| Male | 10 (22.7) |
34 (77.3) |
22 (50.0) |
22 (50.0) |
16 (36.4) |
28 (63.6) |
36 (81.8) |
8 (18.2) |
||||
| Tumour grade | ||||||||||||
| G1 | 6 (26.1) |
17 (73.9) |
0.186a | 15 (65.2) |
8 (34.8) |
0.032 a | 8 (34.8) |
15 (65.2) |
0.268a | 21 (91.3) |
2 (8.7) |
0.347a |
| G2 | 11 (31.4) |
24 (68.6) |
20 (57.1) |
15 (42.9) |
15 (42.9) |
20 (57.1) |
27 (77.1) |
8 (22.9) |
||||
| G3 | 0 (0.0) |
8 (100.0) |
1 (12.5) |
7 (87.5) |
1 (12.5) |
7 (87.5) |
7 (87.5) |
1 (12.5) |
||||
| Tumour site | ||||||||||||
| Tongue | 8 (26.7) |
22 (73.3) |
0.919a | 13 (43.3) |
17 (56.7) |
0.234a | 10 (33.3) |
20 (66.7) |
0.897a | 26 (86.7) |
4 (13.3) |
0.726a |
| Floor of the mouth | 4 (22.2) |
14 (77.8) |
12 (66.7) |
6 (33.3) |
7 (38.9) |
11 (61.1) |
14 (77.8) |
4 (22.2) |
||||
| Buccal mucosa | 5 (27.8) |
13 (72.2) |
11 (61.1) |
7 (38.9) |
7 (38.9) |
11 (61.1) |
15 (83.3) |
3 (16.7) |
||||
| T classification | ||||||||||||
| T1/T2 | 11 (37.9) |
18 (62.1) |
0.045 a | 17 (58.6) |
12 (41.4) |
0.556a | 10 (34.5) |
19 (65.5) |
0.779a | 27 (93.1) |
2 (6.9) |
0.059a |
| T3/T4 | 6 (16.2) |
31 (83.8) |
19 (51.4) |
18 (48.6) |
14 (37.8) |
23 (62.2) |
28 (75.7) |
9 (24.3) |
||||
| N classification | ||||||||||||
| N0 | 7 (18.9) |
30 (81.1) |
0.151a | 20 (54.1) |
17 (45.9) |
0.928a | 10 (27.0) |
27 (73.0) |
0.043 b | 34 (91.9) |
3 (8.1) |
0.035 a |
| N1/N2/N3 | 10 (34.5) |
19 (65.5) |
16 (55.2) |
13 (44.8) |
14 (48.2) |
15 (51.7) |
21 (72.4) |
8 (27.6) |
||||
| Clinical stage | ||||||||||||
| I/II | 7 (33.3) |
14 (66.7) |
0.067b | 13 (61.9) |
8 (38.1) |
0.412a | 6 (28.6) |
15 (71.4) |
0.369a | 19 (90.5) |
2 (9.5) |
0.288a |
| III/IV | 10 (22.2) |
35 (77.8) |
23 (51.1) |
22 (48.9) |
18 (40.0) |
27 (60.0) |
36 (80.0) |
9 (20.0) |
||||
| Survival | ||||||||||||
| Alive | 9 (45.0) |
11 (55.0) |
0.018 a | 12 (60.0) |
8 (40.0) |
0.558a | 6 (30.0) |
14 (70.0) |
0.479a | 19 (95.0) |
1 (5.0) |
0.089b |
| Dead | 8 (17.4) |
38 (82.6) |
24 (52.2) |
22 (47.8) |
18 (39.1) |
28 (60.9) |
36 (78.3) |
10 (21.7) |
||||
| Total OSCC | 17 (25.8) |
49 (74.2) |
36 (54.5) |
30 (45.5) |
24 (36.4) |
42 (63.6) |
55 (83.3) |
11 (16.7) |
||||
a Chi-square test;
b Mann-Whitney U-test;
Bold values indicate statistical significance (p < 0.05).